ScoreWhy is Sun Pharmaceutical Industries Ltd ?
1
Low Debt Company with Strong Long Term Fundamental Strength
- Healthy long term growth as Net Sales has grown by an annual rate of 11.37% and Operating profit at 20.79%
- Company has a low Debt to Equity ratio (avg) at 0 times
- The company has been able to generate a Return on Equity (avg) of 15.21% signifying high profitability per unit of shareholders funds
2
The company has declared Positive results for the last 3 consecutive quarters
- INVENTORY TURNOVER RATIO(HY) Highest at 5.21 times
- CASH AND CASH EQUIVALENTS(HY) Highest at Rs 12,257.42 cr
- NET SALES(Q) Highest at Rs 15,520.54 cr
3
With ROE of 14.8, it has a Expensive valuation with a 5.3 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -2.43%, its profits have risen by 3% ; the PEG ratio of the company is 11.4
4
High Institutional Holdings at 36.94%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Sun Pharma.Inds. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sun Pharma.Inds. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Sun Pharma.Inds.
-1.15%
-0.12
19.95%
Sensex
9.09%
0.69
11.53%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
11.37%
EBIT Growth (5y)
20.79%
EBIT to Interest (avg)
55.35
Debt to EBITDA (avg)
0.28
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.71
Tax Ratio
25.78%
Dividend Payout Ratio
35.13%
Pledged Shares
0.97%
Institutional Holding
36.94%
ROCE (avg)
21.14%
ROE (avg)
15.21%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
34
Industry P/E
33
Price to Book Value
5.26
EV to EBIT
26.34
EV to EBITDA
22.08
EV to Capital Employed
7.00
EV to Sales
6.80
PEG Ratio
11.43
Dividend Yield
0.97%
ROCE (Latest)
25.07%
ROE (Latest)
14.84%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
INVENTORY TURNOVER RATIO(HY)
Highest at 5.21 times
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 12,257.42 cr
NET SALES(Q)
Highest at Rs 15,520.54 cr
PBDIT(Q)
Highest at Rs 4,948.49 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 31.88%
PBT LESS OI(Q)
Highest at Rs 4,137.80 cr.
PAT(Q)
At Rs 3,762.64 cr has Grown at 30.3% (vs previous 4Q average
EPS(Q)
Highest at Rs 14.04
-2What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.54 times
Loading Valuation Snapshot...
Here's what is working for Sun Pharma.Inds.
Inventory Turnover Ratio- Half Yearly
Highest at 5.21 times and Grown
each half year in the last five half yearly periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Net Sales - Quarterly
Highest at Rs 15,520.54 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 4,948.49 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 31.88%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 4,137.80 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 4,137.80 cr has Grown at 22.1% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 3,388.53 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 3,762.64 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 3,762.64 cr has Grown at 30.3% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 2,887.24 CrMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 14.04
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 12,257.42 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Sun Pharma.Inds.
Debtors Turnover Ratio- Half Yearly
Lowest at 3.54 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
